Target Price | $311.38 |
Price | $288.18 |
Potential | 8.05% |
Number of Estimates | 24 |
24 Analysts have issued a price target Amgen 2026 . The average Amgen target price is $311.38. This is 8.05% higher than the current stock price. The highest price target is $400.00 38.80% , the lowest is $185.00 35.80% . | |
A rating was issued by 33 analysts: 14 Analysts recommend Amgen to buy, 16 to hold and 3 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Amgen stock has an average upside potential 2026 of 8.05% . Most analysts recommend the Amgen stock at Hold. |
27 Analysts have issued a sales forecast Amgen 2025 . The average Amgen sales estimate is $35.3b . This is 3.36% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $35.9b 5.32% , the lowest is $34.5b 1.19% .
This results in the following potential growth metrics:
2024 | $33.4b | 18.57% |
---|---|---|
2025 | $35.3b | 5.53% |
2026 | $35.9b | 1.80% |
2027 | $37.0b | 2.97% |
2028 | $37.1b | 0.39% |
2029 | $38.4b | 3.49% |
12 Analysts have issued an Amgen EBITDA forecast 2025. The average Amgen EBITDA estimate is $17.5b . This is 23.16% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $21.4b 51.16% , the lowest is $12.8b 9.44% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $15.3b | 85.55% |
---|---|---|
2025 | $17.5b | 14.59% |
2026 | $17.6b | 0.48% |
2027 | $17.9b | 1.99% |
2028 | $18.5b | 3.59% |
2029 | $18.6b | 0.03% |
2024 | 45.63% | 56.49% |
---|---|---|
2025 | 49.54% | 8.58% |
2026 | 48.90% | 1.29% |
2027 | 48.43% | 0.96% |
2028 | 49.98% | 3.20% |
2029 | 48.31% | 3.34% |
9 Amgen Analysts have issued a net profit forecast 2025. The average Amgen net profit estimate is $7.2b . This is 21.72% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $8.3b 40.22% , the lowest is $6.6b 11.38% .
This results in the following potential growth metrics and future Net Margins:
2024 | $4.1b | 39.11% |
---|---|---|
2025 | $7.2b | 76.56% |
2026 | $7.7b | 6.46% |
2027 | $8.5b | 10.33% |
2028 | $10.5b | 23.90% |
2029 | $12.1b | 15.13% |
2024 | 12.24% | 48.64% |
---|---|---|
2025 | 20.47% | 67.28% |
2026 | 21.41% | 4.59% |
2027 | 22.94% | 7.15% |
2028 | 28.32% | 23.45% |
2029 | 31.50% | 11.23% |
9 Analysts have issued a Amgen forecast for earnings per share. The average Amgen EPS is $13.43 . This is 22.54% higher than earnings per share in the financial year 2024. The highest EPS forecast is $15.47 41.15% , the lowest is $12.29 12.14% .
This results in the following potential growth metrics and future valuations:
2024 | $7.56 | 39.47% |
---|---|---|
2025 | $13.43 | 77.65% |
2026 | $14.30 | 6.48% |
2027 | $15.78 | 10.35% |
2028 | $19.55 | 23.89% |
2029 | $22.50 | 15.09% |
Current | 26.29 | 39.73% |
---|---|---|
2025 | 21.46 | 18.38% |
2026 | 20.15 | 6.10% |
2027 | 18.27 | 9.33% |
2028 | 14.74 | 19.32% |
2029 | 12.81 | 13.09% |
Based on analysts' sales estimates for 2025, the Amgen stock is valued at an EV/Sales of 5.77 and an P/S ratio of 4.39 .
This results in the following potential growth metrics and future valuations:
Current | 5.96 | 19.35% |
---|---|---|
2025 | 5.77 | 3.18% |
2026 | 5.67 | 1.77% |
2027 | 5.50 | 2.89% |
2028 | 5.48 | 0.39% |
2029 | 5.30 | 3.37% |
Current | 4.54 | 18.27% |
---|---|---|
2025 | 4.39 | 3.25% |
2026 | 4.32 | 1.76% |
2027 | 4.19 | 2.89% |
2028 | 4.17 | 0.39% |
2029 | 4.03 | 3.37% |
Analyst | Rating | Action | Date |
---|---|---|---|
Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | May 16 2025 |
Mizuho |
Neutral
➜
Neutral
|
Unchanged | May 07 2025 |
UBS |
Neutral
➜
Neutral
|
Unchanged | May 02 2025 |
RBC Capital |
Outperform
➜
Outperform
|
Unchanged | May 02 2025 |
Cantor Fitzgerald |
➜
Overweight
|
Initiated | Apr 22 2025 |
UBS |
Neutral
➜
Neutral
|
Unchanged | Apr 14 2025 |
Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Apr 09 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
May 16 2025 |
Unchanged
Mizuho:
Neutral
➜
Neutral
|
May 07 2025 |
Unchanged
UBS:
Neutral
➜
Neutral
|
May 02 2025 |
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
May 02 2025 |
Initiated
Cantor Fitzgerald:
➜
Overweight
|
Apr 22 2025 |
Unchanged
UBS:
Neutral
➜
Neutral
|
Apr 14 2025 |
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Apr 09 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.